Daniel Rea
YOU?
Author Swipe
View article: Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)? Open
Combining molecular and clinico-pathologic factors enhances prognostic information. However, the impact of this on actual patient management requires further prospective validation. The trial is registered with clinicaltrials.gov NCT002794…
View article: Greater preservation of SARS‐CoV‐2 neutralising antibody responses following the ChAdOx1‐S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients
Greater preservation of SARS‐CoV‐2 neutralising antibody responses following the ChAdOx1‐S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients Open
Summary Whilst SARS‐CoV‐2 mRNA vaccines generate high neutralising antibodies (nAb) in most individuals, haematopoietic stem cell transplant (HSCT) and chimeric antigen receptor T‐cell (CAR‐T) recipients respond poorly. HSCT/CAR‐T treatmen…
View article: Supplementary Figure S1 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplementary Figure S1 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial Open
Supplemental Figure 1. Continuous risk curves of BCI and BCIN+ for overall 10-year DR in patients who did not receive adjuvant chemotherapy. A: risk of overall 10-year DR as a function of continuous BCI for N0 patients (N=1196); B: risk of…
View article: Supplementary Table S1 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplementary Table S1 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial Open
Supplemental Table 1. Prognostic performance of BCI and BCIN+ optimized cut-points for late DR in all patients with N0 and N1 breast cancers, as well as in HER2- subsets, respectively.
View article: Data from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Data from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial Open
Purpose:Patients with early-stage hormone receptor–positive (HR+) breast cancer face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) is significantly prognostic for overall (0–10 years) a…
View article: Supplementary Figure S2 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplementary Figure S2 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial Open
Supplemental Figure 2. Continuous risk curves of BCI and BCIN+ for late 10-year DR in patients DR-free at 5 years. A: risk of 10-year late DR as a function of continuous BCI for N0 patients (N=1285); B: risk of 10-year late DR as a functio…
View article: Data from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Data from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial Open
Purpose:Patients with early-stage hormone receptor–positive (HR+) breast cancer face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) is significantly prognostic for overall (0–10 years) a…
View article: Supplementary Table S2 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplementary Table S2 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial Open
Supplemental Table 2. Distribution of patients as defined by BCI prognostic (BCI/BCIN+) and BCI predictive (BCI (H/I)).
View article: Supplementary Figure S1 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplementary Figure S1 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial Open
Supplemental Figure 1. Continuous risk curves of BCI and BCIN+ for overall 10-year DR in patients who did not receive adjuvant chemotherapy. A: risk of overall 10-year DR as a function of continuous BCI for N0 patients (N=1196); B: risk of…
View article: Supplementary Figure S2 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplementary Figure S2 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial Open
Supplemental Figure 2. Continuous risk curves of BCI and BCIN+ for late 10-year DR in patients DR-free at 5 years. A: risk of 10-year late DR as a function of continuous BCI for N0 patients (N=1285); B: risk of 10-year late DR as a functio…
View article: Supplementary Table S2 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplementary Table S2 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial Open
Supplemental Table 2. Distribution of patients as defined by BCI prognostic (BCI/BCIN+) and BCI predictive (BCI (H/I)).
View article: Supplementary Table S1 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Supplementary Table S1 from Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial Open
Supplemental Table 1. Prognostic performance of BCI and BCIN+ optimized cut-points for late DR in all patients with N0 and N1 breast cancers, as well as in HER2- subsets, respectively.
View article: Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial
Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor–Positive Postmenopausal Breast Cancer Patients in the TEAM Trial Open
Purpose: Patients with early-stage hormone receptor–positive (HR+) breast cancer face a prolonged risk of recurrence even after adjuvant endocrine therapy. The Breast Cancer Index (BCI) is significantly prognostic for overall (0–10 years) …
View article: Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer
Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. C…
View article: Data from Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study
Data from Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study Open
Purpose:The Breast Cancer Index (BCI) HOXB13/IL17BR (H/I) ratio predicts benefit from extended endocrine therapy in hormone receptor–positive (HR+) early-stage breast cancer. Here, we report the final analysis of the Trans-aTTom study exam…
View article: Supplementary Figure from Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study
Supplementary Figure from Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study Open
Supplementary Figure from Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study
View article: Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT)
Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT) Open
Purpose:The STAKT study examined short-term exposure (4.5 days) to the oral selective pan-AKT inhibitor capivasertib (AZD5363) to determine if this drug can reach its therapeutic target in sufficient concentration to significantly modulate…
View article: Supplementary Figure from Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study
Supplementary Figure from Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study Open
Supplementary Figure from Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study
View article: Supplementary Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT)
Supplementary Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT) Open
Supplementary Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)
View article: Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT)
Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT) Open
Purpose:The STAKT study examined short-term exposure (4.5 days) to the oral selective pan-AKT inhibitor capivasertib (AZD5363) to determine if this drug can reach its therapeutic target in sufficient concentration to significantly modulate…
View article: Supplementary Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT)
Supplementary Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT) Open
Supplementary Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)
View article: Supplementary Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT)
Supplementary Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER<sup>+</sup> Invasive Breast Cancer (STAKT) Open
Supplementary Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)